Abstracts Archive - Page 561 of 2607 - ACR Meeting Abstracts

Abstract Number: 1165 • ACR Convergence 2022
Pathogenicity of IL-17 Producing Cells in HLA-B27 Transgenic Rat Model of Spondyloarthritis
Marie Beaufrère¹, Manon Jacoutot¹, Amel Ait Ali Said¹, Roula Said-Nahal², Gina Cosentino³, Chiara Rizzo³, Maxime Breban⁴ and Simon Glatigny⁴, ¹Paris Saclay University / INSERM 1173, Montigny-le-Bretonneux, France, ²Rheumatology Division - Ambroise Pare Hospital, APHP, Boulogne-Billancourt, France, ³INSERM 1173, Montigny-le-Bretonneux, France, ⁴1INSERM U1173, UFR Simone Veil, Versailles-Saint Quentin / Paris-Saclay University, Montigny-le-Bretonneux, France
Background/Purpose: Spondylarthritis (SpA) is a group of chronic inflammatory disorders with osteoarticular and extraarticular symptoms, including colitis, highly associated with the human leukocyte antigen (HLA)…
Abstract Number: 1159 • ACR Convergence 2022
Uveitis in Psoriatic Arthritis: Study of 406 Patients in a Single University Center
Ana De Vicente-Delmás¹, Lara Sánchez-Bilbao², Vanesa Calvo Río³, David Martínez-López², Alba Herrero-Morant⁴, Eva Galíndez-Agirregoikoa⁵, Nuria Barroso-García⁶, Natalia Palmou-Fontana², Miguel Ángel González-Gay⁷ and Ricardo Blanco⁸, ¹Hospital General Santa María del Puerto, Cádiz, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Valdecilla Hospital, Santander, Spain, ⁴Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ⁵Basurto University Hospital, Bilbao, Spain, ⁶Hospital Universitario Puerta del Mar, Cádiz, Spain, Cádiz, Spain, ⁷Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁸Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: The manifestations of uveitis are well-established in Axial Spondyloarthritis (ax-SpA), but not in Psoriatic Arthritis (PsA). We aimed to assess, in a large unselected…
Abstract Number: 1158 • ACR Convergence 2022
Differential Plasma Levels of S100 Proteins in Male versus Female Patients with Ankylosing Spondylitis
Chan Mi Lee¹, Maricela Haghiac² and Marina Magrey³, ¹University Hospitals, Cleveland, OH, ²Metrohealth Medical Center, Cleveland, OH, ³Case Western Reserve University, University Hospitals, Richfield, OH
Background/Purpose: S100 proteins are a family of 25 calcium-binding cytosolic proteins which are involved in stress and inflammatory responses. S100A4 acts as a negative regulator…
Abstract Number: 1170 • ACR Convergence 2022
Systemic Sclerosis Dermal Fibroblast-derived Exosomes Trigger a Type 1 Interferon Rresponse in Keratinocytes Through TBK1
Jessica Bryon¹, Christopher Wasson¹, Rebecca Ross¹, Elton Zeqiraj¹ and Francesco Del Galdo², ¹University of Leeds, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health and NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom
Background/Purpose: Elevated Type I IFN response is present in blood and affected tissues in systemic sclerosis (SSc) and correlates with disease activity and response to…
Abstract Number: 1171 • ACR Convergence 2022
Distinct Immune Cell Subsets in Systemic Sclerosis-related Interstitial Lung Disease
Phan Saligrama¹, Erin Wilfong², Elise Rizzi³, Leslie Crofford² and Peggy Kendall¹, ¹Washington University, Saint Louis, MO, ²Vanderbilt University Medical Center, Nashville, TN, ³Pennsylvania State University, Hershey, PA
Background/Purpose: The pathogenesis of systemic sclerosis is not well understood. The key differences between immune cell compartments in scleroderma with and without interstitial lung disease…
Abstract Number: 1161 • ACR Convergence 2022
IL-36-receptor Antagonist-Antibodies in Psoriasis and Psoriatic Arthritis
Marie-Christin Hoffmann¹, Natalie Fadle¹, Evi Regitz¹, Klaus-Dieter Preuss¹, Marina Zaks², Elisabeth Stöger³, Vincent Zimmer⁴, Philipp Klemm⁵, Gunter Assmann⁶, Bernhard Thurner⁷, Claudia Pföhler⁸, Joerg Thomas Bittenbring¹, Christoph Kessel⁹ and Lorenz Thurner¹, ¹José Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany, ²Department of Nephrology and Internal Intensive Care, Charité University Medicine Berlin, Campus Virchow Clinic, Berlin, Germany, ³Evangelische Kliniken Essen-Mitte gGmbH, Evangelische Huyssens-Stiftung Essen-Huttrop, Essen, Germany, Essen, Germany, ⁴Department of Medicine, Knappschaftsklinikum Saar, Püttlingen, Germany, Department of Medicine II, Saarland University Medical School, Homburg/Saar, Germany, ⁵Campus Kerckhoff of Justus Liebig University Giessen, Bad Nauheim, Germany, ⁶Klinik für Rheumatologie und klinische Immunologie, Mühlenkreiskliniken, Johannes Wesling Klinikum Minden, Minden, Germany, Minden, Germany, ⁷Department of Pediatrics, Klinikum Kempten, Kempten, Germany, ⁸Department of Dermatology, Saarland University Medical School, Homburg/Saar, Germany, ⁹Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster, Münster, Germany, Münster, Germany
Background/Purpose: Psoriasis arthritis is known as a subtype of seronegative spondylarthritis. However, autoantibodies against the receptor antagonist at tumor necrosis factor receptor 1 and 2…
Abstract Number: 1169 • ACR Convergence 2022
Downregulated Fli1 in Systemic Sclerosis Myeloid Cells Contributes to Enhanced Transendothelial Migration
Pablo Weilg Espejo¹, Taha Dinc², Fatima El Adili³, Maria Trojanowska⁴ and Andreea Bujor⁴, ¹Boston Medical Center, Chelsea, MA, ²Boston University School of Medicine, Boston, MA, ³Boston University School of Medicine, Revere, MA, ⁴Boston University, Boston, MA
Background/Purpose: The mononuclear phagocytic system in Systemic Sclerosis (SSc) is central to fibrogenesis and may contribute to fibrosis via enhanced monocyte migration into injured tissues…
Abstract Number: 1182 • ACR Convergence 2022
Evaluation of Efficacy, Immunogenicity, and Toxicity of a Novel Drug Candidate for Scleroderma-associated Interstitial Lung Disease
Galina Bogatkevich, Ilia Atanelishvili, C. Beth Perry and Richard Silver, Medical University of South Carolina, Charleston, SC
Background/Purpose: Interstitial lung disease (ILD) is the major cause of mortality among scleroderma (systemic sclerosis, SSc) patients. Although immunosuppressive agents and several other drugs such…
Abstract Number: 1176 • ACR Convergence 2022
Immunoglobulins G from Systemic Sclerosis Patients May Alter the Secretome of Dermal Fibroblasts
Aurélien Chepy¹, Marie Duhamel², Solange Vivier³, lucile Guilbert³, Eric Hachulla⁴, Sylvain Dubucquoi³, David Launay³, Michel Salzet² and Vincent Sobanski³, ¹CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France, ²Univ. Lille, Inserm, CHU Lille, U1192 - Protéomique Réponse Inflammatoire Spectrométrie de Masse - PRISM, Lille, France, ³Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France, ⁴University of Lille, LILLE, France
Background/Purpose: Autoantibodies (Aab) are frequent in systemic sclerosis (SSc).Recently, it has been shown that immunoglobulins G (IgG) from SSc promoted a proinflammatory and profibrotic phenotype…
Abstract Number: 1178 • ACR Convergence 2022
Key Features of Human Fibrosing Interstitial Lung Disease Are Captured in a Preclinical Mouse Model upon Repetitive, but Not Single Intratracheal Bleomycin Dosing
David Lauer¹, Janine Schniering², Matthias Brunner¹, Chantal Meier³, Kerstin Klein¹, Oliver Distler⁴ and Britta Maurer¹, ¹Department of Rheumatology and Immunology, University Hospital Bern, University of Bern, Bern, Switzerland, ²Helmholtz Zentrum München, Institute of Lung Health and Immunity (LHI), Comprehensive Pneumonology Center, Munich, Germany, ³Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland
Background/Purpose: Repetitive alveolar epithelial injury together with dysregulated tissue repair is crucial for the transition of acute self-limiting to chronic-persisting inflammation and fibrosis in fibrosing…
Abstract Number: 1174 • ACR Convergence 2022
Cellular Immunotherapy for Systemic Sclerosis
Chanhyuk Park¹, Rajan Bhandari², Jason Gunn³, Timothy Sullivan², Gretel Torres², Joana Murad³, Michael Whitfield⁴ and Patricia Pioli², ¹Geisel School of Medicine at Dartmouth, West Lebanon, NH, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Celdara Medical, Lebanon, ⁴Geisel School of Medicine, Lebanon, NH
Background/Purpose: Pro-fibrotic macrophages (MØs) are implicated in the pathogenesis of systemic sclerosis (SSc). In prior work, we and others have shown that MØs derived from…
Abstract Number: 1185 • ACR Convergence 2022
Interleukin-11 Promotes Fibrosis Through Classic and Trans-signaling Pathway in Systemic Sclerosis
Wenjing Ye¹, Qian Wang¹, Li Zhao², Changcheng Wang³, Dandan Zhang⁴, Mengyu Zhou⁴, Fangfang Chen², Zaihua Zhu², Weiguo Wang², Wenyu Guo⁵, Yun Liu⁴, Hejian Zou² and Yu Xue², ¹epartment of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China, ²Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China, ³Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China, ⁴MOE Key Laboratory of Metabolism and Molecular Medicine, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China, ⁵Clinical Development, I-Mab Biopharma (Hangzhou) Co., Ltd, Shanghai, China
Background/Purpose: Interleukin-11 (IL-11) was found significantly upregulated in Systemic sclerosis (SSc), the aim of this study is to explore the pathological role of IL-11 and…
Abstract Number: 1184 • ACR Convergence 2022
Intracellular Calcium Signals Regulate the Pro-fibrotic Phenotype of Scleroderma Fibroblasts via Calcium/calmodulin-dependent Kinase II
Sirapa Vichaikul¹, William Brodie², Megan Mattichak², Qi Wu², Dinesh Khanna² and Eliza Pei-Suen Tsou², ¹Michigan Medicine, Howell, MI, ²University of Michigan, Ann Arbor, MI
Background/Purpose: We performed an in-depth analysis of the involvement of histone reader bromodomain extra-terminal proteins (BETs) in scleroderma (SSc) fibrosis and showed that JQ1, a…
Abstract Number: 1127 • ACR Convergence 2022
Unsupervised Clustering Analysis of the Serum Proteome Identifies Systemic Sclerosis Patients with Distinctive Clinical Features
Chary Lopez-Pedrera¹, Rafaela Ortega-Castro¹, Tomás Cerdó², Pilar Font¹, María Martinez-Monllor³, Laura Muñoz-Barrera¹, Ismael Sánchez-Pareja², María Carmen Ábalos-Aguilera³, Nuria Barbarroja¹, Eduardo Collantes¹, María Ángeles Aguirre-Zamorano⁴ and Carlos Pérez-Sánchez¹, ¹IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, ³Imibic/ University of Córdoba/ Reina Sofía Hospital, Córdoba, Spain, ⁴Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain
Background/Purpose: Systemic sclerosis (SSc) is an heterogeneous autoimmune disease. There is an unmet need of biomarkers for diagnosis, progression and therapeutic response.This study aimed to…
Abstract Number: 1077 • ACR Convergence 2022
Safety of Avacopan in ANCA-Associated Vasculitis: Combined Data from Three Clinical Trials
Pirow Bekker¹, Peter Merkel² and David Jayne³, ¹ChemoCentryx, San Juan Capistrano, CA, ²U of Pennsylvania, Philadelphia, PA, ³University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Avacopan is approved as adjunctive treatment for adults with ANCA-associated vasculitis (AAV). This study aimed to combine and report on data of the safety…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].